| Market Cap | 6.94M | P/E | 0.00 | EPS this Y | 76.80% | Ern Qtrly Grth | - |
| Income | -8.28M | Forward P/E | -0.57 | EPS next Y | 56.20% | 50D Avg Chg | 11.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -44.00% |
| Dividend | N/A | Price/Book | 0.64 | EPS next 5Y | - | 52W High Chg | -97.00% |
| Recommedations | 2.30 | Quick Ratio | 3.18 | Shares Outstanding | 3.98M | 52W Low Chg | 39.00% |
| Insider Own | 2.39% | ROA | -36.32% | Shares Float | 3.88M | Beta | 2.04 |
| Inst Own | 7.10% | ROE | -100.03% | Shares Shorted/Prior | 193.53K/2.62K | Price | 7.03 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 155,024 | Target Price | 4.67 |
| Oper. Margin | - | Earnings Date | Nov 6 | Volume | 56,065 | Change | -10.67% |
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.